Gluco Mild Ingredients: The Seven Botanicals Inside

A creeping marsh plant whose leaf has been used across South and South-East Asia for centuries and whose modern file is small, old and unusually precise about quantity. The trials did not test the leaf. They tested a standardised total triterpenic fraction, which is a concentrate of four named molecules pulled out of it, and the dose-ranging work compared 90 mg a day against 180 mg a day in people with venous hypertension. The larger figure read better on ankle swelling and on capillary leak.

What that buys a reader here is a rare thing in botanical research: a published opinion about how much. The 2021 review of the plant walks through the chemistry those numbers were standardising. A leaf extract in a dropper is a different preparation with a different concentration, and the graphic gives no figure to line up against either one.

The red fruit of a thorn tree, dried and extracted, and the only ingredient on this list with a two-year randomised trial behind it. That trial used 900 mg a day of a standardised extract called WS 1442, gave it to 2,681 people who were already receiving prescribed treatment for heart failure, and ran for 24 months.

Read that sentence twice before deciding what it says about a dropper. The benefit-risk assessment of the same extract treats it as a pharmaceutical preparation, because in Germany that is what it is. Hawthorn is the strongest name on this graphic and the one whose evidence sits furthest from the way this bottle is bought and taken.

Seed extract from the conker tree, standardised in every serious study to escin, a mixture of saponins that a 2023 chemical account describes as dozens of closely related molecules rather than one compound. Escin is what makes the preparation work and also what makes it worth taking after food.

Its clinical record is the tidiest in the category. The Cochrane review gathered seventeen randomised trials and concluded that horse chestnut seed extract reduces leg pain, swelling and itching against placebo in chronic venous insufficiency. The trials that did it were counted in milligrams of escin, which is the one number this graphic cannot supply.

A North American woodland mint whose root reached the shelf through nineteenth-century practice rather than through trials. The whole modern literature is a 1999 paper isolating a new flavanone from the plant, and the historical record is represented here by an 1887 note in the British Medical Journal.

No randomised trial of stone root exists, in circulation or in anything else, at any quantity. This desk says so on the ingredient it would be easiest to say nothing about, and no effect is claimed for it anywhere on this website.

A square-stemmed mint named for the heart in both halves of its Latin binomial, which is a statement about tradition rather than about evidence. The update to the European assessment report and a review of its phytochemistry both describe long traditional cardiotonic use, alkaloids and flavonoid glycosides, and laboratory pharmacology in cells and animals.

What neither describes is a randomised cardiovascular trial in people, because there is not one. Traditional use is a reason a plant is on a label. It is not a result, and this website does not print it as one. The one hard consequence of what is in motherwort is a safety point rather than a benefit, and who it is for states it by name.

A stiff Mediterranean shrub whose rootstock carries ruscogenins. A twelve-week placebo-controlled trial in 148 women measured leg volume rather than asking people how they felt, which is why it is quoted so often, and a 2025 review of the plant sets out the chemistry behind it.

One caveat travels with this name everywhere. Most of the pooled evidence is for a combination product in which butcher's broom is given with hesperidin methyl chalcone and vitamin C, so the result belongs to the three together. Neither of the other two is on this graphic.

The seed left behind by winemaking, extracted for proanthocyanidins, and the most studied name on the list outside hawthorn. A twelve-week trial in prehypertension measured how well the lining of an artery relaxes, and a formal safety evaluation of the extract covers what happens at quantities far above what any supplement delivers.

Grape seed is also where this product's name becomes awkward, and the awkwardness is answered on the benefits page rather than avoided. It is the one ingredient of the seven with published glycaemic work behind it, and that work is not a claim this label makes.